—

Decheng Capital LLC

Q1 2026 13F Holdings

  • Location
    menlo park, CA
  • Num holdings

    14

  • Value ($000)

    $661,316

  • Date Filed
    05/13/2026
  • Form type
    13F-HR
  • CIK
    0002010850
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q1 2026 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
C
CGON

CG ONCOLOGY INC

COM
156944100
$431.23M
65 %

6,371,669

N
NUVB

Nuvation Bio Inc.

COM
67080N101
$111.34M
17 %

25,954,439

---

Upstream Bio Inc.

COM
91678A107
$24.52M
4 %

2,724,868

A
ACRS

Aclaris Therapeutics, Inc.

COM
00461U105
$15.16M
2 %

4,041,736

---

AARDVARK THERAPEUTICS INC

COM
002942100
$14.77M
2 %

3,917,299

L
LYEL

Lyell Immunopharma, Inc.

COM
55083R104
$13.88M
2 %

692,050

---

NEWAMSTERDAM PHARMA CO NV

COM
N62509109
$10.41M
2 %

325,057

R
RCUS

Arcus Biosciences, Inc

COM
03969F109
$10.32M
2 %

477,819

R
RVMD

REVOLUTION MEDICINES INC(NSM)

COM
76155X100
$9.09M
1 %

93,500

E
EQ

Equillium Inc.

COM
29446K106
$8.89M
1 %

4,447,308

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 10 of 14